BOUT - ETF AI Analysis
Top Page
Innovator IBD Breakout Opportunities ETF (BOUT)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, showing solid momentum in its strategy.
Leading Financial and Health Care Exposure
A large portion of the fund is invested in financial and health care companies, many of which have shown steady to strong performance.
Top Holdings with Strong Individual Results
Several of the largest positions, especially in therapeutics and major banks, have posted strong year-to-date returns that support the fund’s overall results.
Negative Factors
High Expense Ratio
The fund charges relatively high fees compared with many ETFs, which can reduce the net return investors keep over time.
Sector Concentration Risk
Heavy weighting in financial and health care stocks means the fund is more exposed if either of these sectors faces a downturn.
Limited Geographic Diversification
With almost all assets in U.S. companies, the ETF offers little exposure to other regions, which can increase sensitivity to U.S.-specific economic and market risks.
BOUT vs. SPDR S&P 500 ETF (SPY)
AUM15.13M
RegionNorth America
Expense Ratio0.80%
Beta0.91
IssuerCapForce
Inception DateSep 13, 2018
Dividend Yield0.29%
Asset ClassEquity
Index TrackedIBD Breakout Stocks Total Return
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,303
30 Day Avg. Volume2,210
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
48.17Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering26
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BOUT Summary
The Innovator IBD Breakout Opportunities ETF (BOUT) is an exchange-traded fund that follows the IBD Breakout Stocks Total Return index, focusing on U.S. companies that Investor’s Business Daily believes are ready for strong price moves. It mainly holds financial and health care stocks, including well-known names like Bank of America and Goldman Sachs, along with smaller, fast-growing biotech firms. Someone might invest in BOUT for growth and to add a different mix of stocks to their portfolio. A key risk is that these “breakout” stocks can be very volatile and may go up or down quickly with market swings.
How much will it cost me?The Innovator IBD Breakout Opportunities ETF (BOUT) has an expense ratio of 0.85%, which means you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying breakout opportunities in the market rather than passively tracking an index.
What would affect this ETF?The Innovator IBD Breakout Opportunities ETF (BOUT), with its focus on U.S. growth-oriented stocks in sectors like technology and industrials, could benefit from advancements in innovation and increased corporate spending in these areas. However, rising interest rates or economic slowdowns could negatively impact growth-focused companies, especially in sectors like technology and healthcare, which are sensitive to changes in borrowing costs and consumer demand.
BOUT Top 10 Holdings
BOUT is leaning heavily into U.S. health care, with names like Natera, Guardant Health, and Hinge Health powering the fund thanks to rising momentum and upbeat growth stories, even if profitability is still a work in progress. TG Therapeutics adds to that breakout feel, while Target Hospitality brings a more mixed, recently lagging note despite strong contracts earlier in the year. Eton Pharmaceuticals has been a standout over the longer run but is losing a bit of steam in the near term. Overall, this is a concentrated, growth-first, U.S.-centric bet on medical and niche industrial winners.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Aura Minerals | 7.14% | $1.06M | $7.65B | 147.12% | 61 Neutral | |
| Hinge Health, Inc. Class A | 7.12% | $1.05M | $8.30B | 106.67% | 70 Outperform | |
| Daily Journal | 6.93% | $1.02M | $884.89M | 53.96% | 72 Outperform | |
| Natera | 6.77% | $1.00M | $57.76B | 136.73% | 73 Outperform | |
| Embraer | 6.70% | $990.52K | $12.92B | 26.98% | 69 Neutral | |
| Zeta Global Holdings Corp | 6.16% | $910.27K | $8.31B | 79.84% | 67 Neutral | |
| Eton Pharmaceuticals | 6.02% | $889.52K | $1.58B | 180.82% | 56 Neutral | |
| BeOne Medicines | 5.95% | $879.88K | $39.40B | 10.74% | 61 Neutral | |
| Micron | 5.89% | $870.11K | $1.16T | 466.63% | 79 Outperform | |
| The Chefs' Warehouse | 5.82% | $860.12K | $4.66B | 100.21% | 72 Outperform |
BOUT Technical Analysis
Negative
―
Price Trends
44.16
Negative
45.55
Negative
43.17
Negative
Market Momentum
-0.39
Negative
44.32
Neutral
34.89
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BOUT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 43.04, equal to the 50-day MA of 44.16, and equal to the 200-day MA of 43.17, indicating a bearish trend. The MACD of -0.39 indicates Negative momentum. The RSI at 44.32 is Neutral, neither overbought nor oversold. The STOCH value of 34.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOUT.
BOUT Peer Comparison
Comparison Results
Performance Comparison
BOUT
Innovator IBD Breakout Opportunities ETF
42.30
3.40
8.74%
BAMD
Brookstone Dividend Stock ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
VAMO
Cambria Value & Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents